Aphios   Report issue

For profit Phase 2
Founded: Woburn MA United States (1993)

Organization Overview

First Clinical Trial
2020
NCT03813095
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Aphios

Active Ingredients

Drugs in Phase 2 Trials (2)

aph-1105 (1 trial)

cannabidiol (Epidiolex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Behavior, Addictive (Phase 2)

Dementia (Phase 2)

Opioid-Related Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2